TO: Hospitals
Regional Cancer Programs
Heads of Medical Oncology
Ontario Cancer Leads and Drug Advisory Committees
Chairs of Disease Site Groups
Regional Vice Presidents

FROM: Scott Gavura, Director, Provincial Drug Reimbursement Programs

CC: Dr. Leta Forbes, Provincial Head, Systemic Treatment Program
Dr. Kelvin Chan, Clinical Lead, Provincial Drug Reimbursement Programs
Dr. Paul Gibson, Associate Medical Director, Clinical Affairs, Pediatric Oncology Group of Ontario (POGO)
David Schachow, Director, Drug Programs Delivery Branch, Drugs and Devices Division

DATE: April 11, 2019

SUBJECT: Provincial Drug Reimbursement Programs (PDRP) Update
○ Dexrazoxane Supply Status Update

PLEASE DISTRIBUTE TO ALL CANCER CARE PROVIDERS

A. Dexrazoxane Supply Status Update

Cancer Care Ontario (CCO) has been informed that Pfizer Canada has received a limited quantity of US-labelled dexrazoxane (Zinecard™) in the 250 mg format as a temporary measure to help mitigate the impact of this shortage until the Canadian product is available (estimated resupply date: May 10, 2019). Please refer to the enclosed ‘Dear Customer’ and ‘Dear Health Care Professional’ letters from Pfizer Canada, dated April 11, 2019, for more information on estimated availability and key differences between the Canadian and US-labelled products.

B. Drug Shortage Questions?

Please direct any questions for CCO on drug shortages to Ron Fung, Clinical Program Manager, Provincial Drug Reimbursement Programs at ron.fung@cancercare.on.ca.